Sandra Brunelleschi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sandra Brunelleschi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Fantozzi
Department of Drug Science and Technology University of Turin Turin Italy
8 shared publications Ilario Viano
11Department of Medical Sciences, University of Piemonte Orientale ‘A. Avogadro', Via Solaroli, 17 - 28100 NOVARA (Italy)
5 shared publicationsEmanuela Masini
University of Florence
4 shared publications- Patrizio Blandina
University of Florence
4 shared publications P. F. Mannaioni
University of Florence
3 shared publicationsAntonio Battaglia
2 shared publications
Latest Publications
- 1 January 2007
- Published by Springer Nature in Drugs
- Vol. 67 (9) , 1243-1255
Glucocorticoids in the Prevention of??Restenosis After Coronary Angioplasty
Vessel luminal narrowing after percutaneous coronary intervention (PCI) is characterised by platelet aggregation, release of growth factors, inflammatory cell infiltration, medial smooth muscle cell (SMC) proliferation, proteoglycan deposition and extracellular matrix remodelling. It is broadly accepted that the central mechanism at the basis of the whole pathophysiological process of restenosis is inflammation, triggered by vascular injury and activated through autocrine or paracrine mediators. Glucocorticosteroids exert beneficial effects on platelet function, on SMC proliferation and on collagen synthesis as well as inflammatory cell migration and activation, thus interfering with several steps of the cascade leading to neointima formation and subsequent late lumen loss. Initial experiences with systemic administration of glucocorticoids after PCI failed to confirm the expected benefits of this treatment, probably as a result of inadequate dosage and pharmacokinetic calculations. Recently a short-term, high-dose immunosuppressive treatment scheme with oral prednisone has demonstrated remarkable clinical and angiographic results when prednisone was given orally at a dose of 1 mg/kg for 10 days, 0.5 mg/kg for 20 days and 0.25 mg/kg for 15 days. This treatment has dramatically reduced the incidence of clinical vascular events at 1 year compared with controls (relative risk 0.34; 95% CI 0.12, 0.96; p = 0.006) and reduced the incidence of angiographic restenosis below 10% in different clinical and angiographie subsets. Secondary effects of a short course of glucocorticoids are generally minor, predictable and reversible: gastric pain, water and salt retention and worsened hypertension manifest in nearly 10% of patients. The addition of diuretics and acid suppressants before discharge, and the upgrading of antihypertensive medication thereafter, if needed, are useful preventive measures to control these temporary disorders. A routine blood cell count 4 weeks after PCI is advised in patients receiving thienopyridines (clopidogrel or ticlopidine) in addition to prednisone to rule out infrequent haematological dyscrasias. Emerging evidence supports this strategy as a convenient and well tolerated alternative to more expensive and complex revascularisation procedures such as drug eluting stent (DES) implantation or cardiac surgery, provided that the treatment is reserved for carefully selected candidates, i.e. after the exclusion of those with diabetes mellitus, a recent transmural myocardial infarction, or contraindications to the administration of a short-course of high-dose glucocorticoster-oids. The recent concerns regarding the long-term safety of first-generation DES and the as yet undetermined duration of dual anti-platelet treatment, further supports the need for a simple pharmacological treatment that can be applied in a large percentage of patients currently treated with PCI. Multicentre randomised studies aimed at defining the efficacy and safety of oral prednisone treatment compared with metallic stents and DES are ongoing, and will become available in upcoming years.
- 1 January 2007
- Published by Springer Nature in Drugs
- Vol. 67 (9) , 1243-1255
Glucocorticoids in the Prevention of??Restenosis After Coronary Angioplasty
Vessel luminal narrowing after percutaneous coronary intervention (PCI) is characterised by platelet aggregation, release of growth factors, inflammatory cell infiltration, medial smooth muscle cell (SMC) proliferation, proteoglycan deposition and extracellular matrix remodelling. It is broadly accepted that the central mechanism at the basis of the whole pathophysiological process of restenosis is inflammation, triggered by vascular injury and activated through autocrine or paracrine mediators. Glucocorticosteroids exert beneficial effects on platelet function, on SMC proliferation and on collagen synthesis as well as inflammatory cell migration and activation, thus interfering with several steps of the cascade leading to neointima formation and subsequent late lumen loss. Initial experiences with systemic administration of glucocorticoids after PCI failed to confirm the expected benefits of this treatment, probably as a result of inadequate dosage and pharmacokinetic calculations. Recently a short-term, high-dose immunosuppressive treatment scheme with oral prednisone has demonstrated remarkable clinical and angiographic results when prednisone was given orally at a dose of 1 mg/kg for 10 days, 0.5 mg/kg for 20 days and 0.25 mg/kg for 15 days. This treatment has dramatically reduced the incidence of clinical vascular events at 1 year compared with controls (relative risk 0.34; 95% CI 0.12, 0.96; p = 0.006) and reduced the incidence of angiographic restenosis below 10% in different clinical and angiographie subsets. Secondary effects of a short course of glucocorticoids are generally minor, predictable and reversible: gastric pain, water and salt retention and worsened hypertension manifest in nearly 10% of patients. The addition of diuretics and acid suppressants before discharge, and the upgrading of antihypertensive medication thereafter, if needed, are useful preventive measures to control these temporary disorders. A routine blood cell count 4 weeks after PCI is advised in patients receiving thienopyridines (clopidogrel or ticlopidine) in addition to prednisone to rule out infrequent haematological dyscrasias. Emerging evidence supports this strategy as a convenient and well tolerated alternative to more expensive and complex revascularisation procedures such as drug eluting stent (DES) implantation or cardiac surgery, provided that the treatment is reserved for carefully selected candidates, i.e. after the exclusion of those with diabetes mellitus, a recent transmural myocardial infarction, or contraindications to the administration of a short-course of high-dose glucocorticoster-oids. The recent concerns regarding the long-term safety of first-generation DES and the as yet undetermined duration of dual anti-platelet treatment, further supports the need for a simple pharmacological treatment that can be applied in a large percentage of patients currently treated with PCI. Multicentre randomised studies aimed at defining the efficacy and safety of oral prednisone treatment compared with metallic stents and DES are ongoing, and will become available in upcoming years.
- 1 November 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 134 (6) , 1285-1295
Macrophage Stimulating Protein (MSP) evokes superoxide anion production by human macrophages of different origin
Macrophage Stimulating Protein (MSP), a serum factor related to Hepatocyte Growth Factor, was originally discovered to stimulate chemotaxis of murine resident peritoneal macrophages. MSP is the ligand for Ron, a member of the Met subfamily of tyrosine kinase receptors. The effects of MSP on human macrophages and the role played in human pathophysiology have long been elusive. We show here that human recombinant MSP (hrMSP) evokes a dose‐dependent superoxide anion production in human alveolar and peritoneal macrophages as well as in monocyte‐derived macrophages, but not in circulating human monocytes. Consistently, the mature Ron protein is expressed by the MSP responsive cells but not by the unresponsive monocytes. The respiratory burst evoked by hrMSP is quantitatively higher than the one induced by N‐formylmethionyl‐leucyl‐phenylalanine and similar to phorbol myristate acetate‐evoked one. To investigate the mechanisms involved in NADPH oxidase activation, leading to superoxide anion production, different signal transduction inhibitors were used. By using the non selective tyrosine kinase inhibitor genistein, the selective c‐Src inhibitor PP1, the tyrosine phosphatase inhibitor sodium orthovanadate, the phosphatidylinositol 3‐kinase inhibitor wortmannin, the p38 inhibitor SB203580, the MEK inhibitor PD098059, we demonstrate that hrMSP‐evoked superoxide production is mediated by tyrosine kinase activity, requires the activation of Src but not of PI 3‐kinase. We also show that MAP kinase and p38 signalling pathways are involved. These results clearly indicate that hrMSP induces the respiratory burst in human macrophages but not in monocytes, suggesting for the MSP/Ron complex a role of activator as well as of possible marker for human mature macrophages. British Journal of Pharmacology (2001) 134, 1285–1295; doi:10.1038/sj.bjp.0704356
- 1 November 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 134 (6) , 1285-1295
Macrophage Stimulating Protein (MSP) evokes superoxide anion production by human macrophages of different origin
Macrophage Stimulating Protein (MSP), a serum factor related to Hepatocyte Growth Factor, was originally discovered to stimulate chemotaxis of murine resident peritoneal macrophages. MSP is the ligand for Ron, a member of the Met subfamily of tyrosine kinase receptors. The effects of MSP on human macrophages and the role played in human pathophysiology have long been elusive. We show here that human recombinant MSP (hrMSP) evokes a dose‐dependent superoxide anion production in human alveolar and peritoneal macrophages as well as in monocyte‐derived macrophages, but not in circulating human monocytes. Consistently, the mature Ron protein is expressed by the MSP responsive cells but not by the unresponsive monocytes. The respiratory burst evoked by hrMSP is quantitatively higher than the one induced by N‐formylmethionyl‐leucyl‐phenylalanine and similar to phorbol myristate acetate‐evoked one. To investigate the mechanisms involved in NADPH oxidase activation, leading to superoxide anion production, different signal transduction inhibitors were used. By using the non selective tyrosine kinase inhibitor genistein, the selective c‐Src inhibitor PP1, the tyrosine phosphatase inhibitor sodium orthovanadate, the phosphatidylinositol 3‐kinase inhibitor wortmannin, the p38 inhibitor SB203580, the MEK inhibitor PD098059, we demonstrate that hrMSP‐evoked superoxide production is mediated by tyrosine kinase activity, requires the activation of Src but not of PI 3‐kinase. We also show that MAP kinase and p38 signalling pathways are involved. These results clearly indicate that hrMSP induces the respiratory burst in human macrophages but not in monocytes, suggesting for the MSP/Ron complex a role of activator as well as of possible marker for human mature macrophages. British Journal of Pharmacology (2001) 134, 1285–1295; doi:10.1038/sj.bjp.0704356
- 1 November 1999
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 8 (11) , 1873-1891
Tachykinin receptor modulators: novel therapeutics for rheumatoid arthritis
The activation of a cellular immune response in a genetically susceptible individual is widely recognised as a main step in triggering rheumatoid arthritis (RA). The tachykinins, substance P (SP) and neurokinin A (NKA), can play a major role in different immune diseases. In patients with inflammatory joint disease, elevated levels of SP have been demonstrated in the synovial fluid of affected joints. It is well known that SP and, to a lesser extent, NKA are deeply involved in the processing of nociceptive signals and exert many pro-inflammatory actions, which may be elicited by an increased neuronal neurokinin release in arthritis; the mechanism behind this increase remains to be fully elucidated. Different observations suggest that one approach to the treatment of RA might be to inhibit the local effects of neurokinins in the affected joints. This review will summarise the more relevant aspects of this topic.
- 1 November 1999
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 8 (11) , 1873-1891
Tachykinin receptor modulators: novel therapeutics for rheumatoid arthritis
The activation of a cellular immune response in a genetically susceptible individual is widely recognised as a main step in triggering rheumatoid arthritis (RA). The tachykinins, substance P (SP) and neurokinin A (NKA), can play a major role in different immune diseases. In patients with inflammatory joint disease, elevated levels of SP have been demonstrated in the synovial fluid of affected joints. It is well known that SP and, to a lesser extent, NKA are deeply involved in the processing of nociceptive signals and exert many pro-inflammatory actions, which may be elicited by an increased neuronal neurokinin release in arthritis; the mechanism behind this increase remains to be fully elucidated. Different observations suggest that one approach to the treatment of RA might be to inhibit the local effects of neurokinins in the affected joints. This review will summarise the more relevant aspects of this topic.
- 1 June 1999
- Published by Elsevier in Life Sciences
- Vol. 65 (5) , PL59-PL65
Coronary effects of cyclovirobuxine D in anesthetized pigs and in isolated porcine coronary arteries
- 1 June 1999
- Published by Elsevier in Life Sciences
- Vol. 65 (5) , PL59-PL65
Coronary effects of cyclovirobuxine D in anesthetized pigs and in isolated porcine coronary arteries
- 1 September 1997
- Published by Elsevier in Life Sciences
- Vol. 61 (17) , PL255-PL261
Hemodynamic effects of the intravenous administration of cyclorirobuxine D in anesthetized pigs
- 1 September 1997
- Published by Elsevier in Life Sciences
- Vol. 61 (17) , PL255-PL261
Hemodynamic effects of the intravenous administration of cyclorirobuxine D in anesthetized pigs
- 1 December 1994
- Published by Elsevier in Pharmacological Research
- Vol. 30 (4) , 355-356
Pathophysiology of leukocytes: from inflammation to ischaemia-reperfusion syndrome
- 1 December 1994
- Published by Elsevier in Pharmacological Research
- Vol. 30 (4) , 355-356
Pathophysiology of leukocytes: from inflammation to ischaemia-reperfusion syndrome
- 22 September 1994
- Published by Elsevier in European Journal of Pharmacology
- Vol. 263 (1-2) , 223-226
Adenosine modulation of primed human neutrophils
- 22 September 1994
- Published by Elsevier in European Journal of Pharmacology
- Vol. 263 (1-2) , 223-226
Adenosine modulation of primed human neutrophils
- 31 December 1992
- Published by Elsevier in Life Sciences
- Vol. 51 (20) , PL177-PL181
Evidence for tachykinin NK-2B-like receptors in guinea-pig alveolar macrophages
- 31 December 1992
- Published by Elsevier in Life Sciences
- Vol. 51 (20) , PL177-PL181
Evidence for tachykinin NK-2B-like receptors in guinea-pig alveolar macrophages
- 30 September 1992
- Published by Elsevier in Pharmacological Research
- Vol. 26, 42-43
Neuropeptide-leukocyte interactions: Examples of pharmacological modulation
- 30 September 1992
- Published by Elsevier in Pharmacological Research
- Vol. 26, 42-43
Neuropeptide-leukocyte interactions: Examples of pharmacological modulation
- 1 June 1992
- Published by Elsevier in Human Pathology
- Vol. 23 (6) , 627-634
Neutrophils as mediators of human skeletal muscle ischemia-reperfusion syndrome
- 1 June 1992
- Published by Elsevier in Human Pathology
- Vol. 23 (6) , 627-634
Neutrophils as mediators of human skeletal muscle ischemia-reperfusion syndrome